JP2013528607A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013528607A5 JP2013528607A5 JP2013511702A JP2013511702A JP2013528607A5 JP 2013528607 A5 JP2013528607 A5 JP 2013528607A5 JP 2013511702 A JP2013511702 A JP 2013511702A JP 2013511702 A JP2013511702 A JP 2013511702A JP 2013528607 A5 JP2013528607 A5 JP 2013528607A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody according
- antibody
- disease
- conservative
- forms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000030533 eye disease Diseases 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 6
- 208000002780 macular degeneration Diseases 0.000 claims 5
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 4
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 4
- 230000002491 angiogenic effect Effects 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010063381 Polypoidal choroidal vasculopathy Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000001491 myopia Diseases 0.000 claims 2
- 230000004379 myopia Effects 0.000 claims 2
- 201000003142 neovascular glaucoma Diseases 0.000 claims 2
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 claims 1
- 208000009043 Chemical Burns Diseases 0.000 claims 1
- 208000021089 Coats disease Diseases 0.000 claims 1
- 206010061788 Corneal infection Diseases 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000019878 Eales disease Diseases 0.000 claims 1
- 241001071795 Gentiana Species 0.000 claims 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000008709 Retinal Telangiectasis Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002497 edematous effect Effects 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34927110P | 2010-05-28 | 2010-05-28 | |
| US61/349,271 | 2010-05-28 | ||
| PCT/EP2011/058777 WO2011147984A1 (en) | 2010-05-28 | 2011-05-27 | Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013528607A JP2013528607A (ja) | 2013-07-11 |
| JP2013528607A5 true JP2013528607A5 (OSRAM) | 2014-06-26 |
| JP5990511B2 JP5990511B2 (ja) | 2016-09-14 |
Family
ID=44276158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013511702A Expired - Fee Related JP5990511B2 (ja) | 2010-05-28 | 2011-05-27 | 血管新生に基づく眼障害の処置のための抗ｃｄ１６０特異的抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9045544B2 (OSRAM) |
| EP (1) | EP2575881B1 (OSRAM) |
| JP (1) | JP5990511B2 (OSRAM) |
| KR (1) | KR101847572B1 (OSRAM) |
| CN (2) | CN102892432A (OSRAM) |
| BR (1) | BR112012030318A2 (OSRAM) |
| CA (1) | CA2796312C (OSRAM) |
| DK (1) | DK2575881T3 (OSRAM) |
| ES (1) | ES2606627T3 (OSRAM) |
| PL (1) | PL2575881T3 (OSRAM) |
| WO (1) | WO2011147984A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10561707B2 (en) * | 2013-09-08 | 2020-02-18 | Technion Research And Development Foundation Ltd. | Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases |
| WO2015168619A1 (en) * | 2014-05-02 | 2015-11-05 | Mayo Foundation For Medical Education And Research | Individualized treatment of eye disease |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| BR112019008345A8 (pt) * | 2016-10-25 | 2023-03-07 | Inst Nat Sante Rech Med | Anticorpos monoclonais ligados à isoforma transmembrana cd160 |
| FR3061716B1 (fr) * | 2017-01-06 | 2019-05-17 | Elsalys Biotech | Nouveaux composes ciblant le cd160 humain |
| JP2020532586A (ja) * | 2017-08-31 | 2020-11-12 | シンガポール ヘルス サービシーズ プライベート リミテッド | 網膜血管性疾患の処置のためのａｎｇｉｏ−３ |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021138409A2 (en) * | 2019-12-31 | 2021-07-08 | Medstar Health, Inc. | Anti-cd160 binding molecules for treating diseases |
| CA3187272A1 (en) | 2020-10-08 | 2022-04-14 | Thorsten Ross | Trispecific binders |
| EP4376958A1 (en) | 2021-07-30 | 2024-06-05 | Affimed GmbH | Duplexbodies |
| JP2025532464A (ja) | 2022-09-15 | 2025-10-01 | アビディキュア アイピー ビー．ブイ． | Ｎｋ細胞の腫瘍標的化のための多重特異性抗原結合タンパク質及びその使用 |
| WO2025191136A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof |
| WO2025191133A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Il-21 muteins, fusion proteins comprising the same and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| EP0628078B1 (en) | 1992-12-11 | 1999-12-08 | The Dow Chemical Company | Multivalent single chain antibodies |
| AU5253898A (en) | 1996-11-12 | 1998-06-03 | Dana-Farber Cancer Institute | Recombinant by55 and nucleic acids encoding same |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| FR2794977B1 (fr) * | 1999-06-18 | 2003-10-31 | Commissariat Energie Atomique | Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention |
| EP1626059A1 (en) | 2004-08-09 | 2006-02-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2 |
| JP2009525282A (ja) * | 2006-01-30 | 2009-07-09 | （オーエスアイ）アイテツク・インコーポレーテツド | 血管新生疾患の治療のための組み合わせ療法 |
| AR062239A1 (es) | 2007-08-07 | 2008-10-22 | Civil De Estudios Superiores A | Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal |
-
2011
- 2011-05-27 CN CN201180024138XA patent/CN102892432A/zh active Pending
- 2011-05-27 EP EP11728594.0A patent/EP2575881B1/en active Active
- 2011-05-27 ES ES11728594.0T patent/ES2606627T3/es active Active
- 2011-05-27 PL PL11728594T patent/PL2575881T3/pl unknown
- 2011-05-27 CA CA2796312A patent/CA2796312C/en active Active
- 2011-05-27 BR BR112012030318A patent/BR112012030318A2/pt not_active Application Discontinuation
- 2011-05-27 CN CN201710912201.2A patent/CN107648605A/zh active Pending
- 2011-05-27 JP JP2013511702A patent/JP5990511B2/ja not_active Expired - Fee Related
- 2011-05-27 DK DK11728594.0T patent/DK2575881T3/en active
- 2011-05-27 WO PCT/EP2011/058777 patent/WO2011147984A1/en not_active Ceased
- 2011-05-27 US US13/697,699 patent/US9045544B2/en active Active
- 2011-05-27 KR KR1020127034345A patent/KR101847572B1/ko not_active Expired - Fee Related
-
2015
- 2015-06-02 US US14/728,253 patent/US10208124B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013528607A5 (OSRAM) | ||
| JP2016504416A5 (OSRAM) | ||
| JP2010528047A5 (OSRAM) | ||
| RU2014113046A (ru) | Профилактика и лечение патологических состояний глаз, вызванных комплементом | |
| JP2020079246A5 (OSRAM) | ||
| RU2015121755A (ru) | Антагонисты ил-6 и их применение | |
| JP2010526028A5 (OSRAM) | ||
| JP2014534239A5 (OSRAM) | ||
| JP2018527327A5 (OSRAM) | ||
| JP2019504882A5 (OSRAM) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2012525128A5 (OSRAM) | ||
| JP2014533239A5 (OSRAM) | ||
| JP2017500018A5 (OSRAM) | ||
| JP2011518546A5 (OSRAM) | ||
| PH12014500220A1 (en) | Anti-vegf single variable domains fused to fc domains | |
| JP2014502955A5 (OSRAM) | ||
| JP2014532072A5 (OSRAM) | ||
| RU2017120360A (ru) | Биспецифические антитела и способы их применения в офтальмологии | |
| JP2017515811A5 (OSRAM) | ||
| JP2017507657A5 (OSRAM) | ||
| RU2017120358A (ru) | Анти-il-1-бета антитела и способы их применения | |
| RU2018119014A (ru) | АНТИТЕЛА ПРОТИВ Нtr1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2018530331A5 (OSRAM) | ||
| JP2017506669A5 (ja) | 膠芽腫の治療に使用するための組成物及びその使用 |